Dapagliflozin and Right Heart Function After Off-Pump Heart Bypass Surgery
Observes dapagliflozin's effect on right heart function after bypass surgery in 72 patients.
Plain-language title generated from the registry record
Registry title: Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting
Key facts
- Where
- Pyatigorsk, RussiaSee the site
Where in Russia
- Pyatigorsk City Clinical Hospital Number 1Pyatigorsk, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pyatigorsk City Clinical Hospital Number 1
- Trial code
- NCT07601867
- Record updated
- 17 June 2026
- Original description
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction <50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).Read full original descriptionShow less
Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Artery Bypass Grafting: a Prospective Single-Center Study
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction <50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).
Inclusion: Age ≥ 18 years; Elective isolated off-pump coronary artery bypass grafting (OPCAB); Left ventricular ejection fraction (LVEF) < 50% documented on pre-operative echocardiography; Written informed consent.
Exclusion: Concomitant valve surgery; Conversion to on-pump during surgery; Previous CABG or any prior cardiac surgery; Contraindication to SGLT2 inhibitors; Perioperative myocardial infarction (as defined by the Fourth Universal Definition of MI); More than moderate valvular heart disease; Severe chronic kidney disease (eGFR < 25 mL/min/1.73 m²); Emergency or urgent CABG; Cardiogenic shock; Persistent atrial fibrillation or atrial flutter at the time of echocardiographic examination); Inability to obtain adequate echocardiographic windows; Pregnancy or breastfeeding.